Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 35323-91-2
2. Ent-epicatechin
3. D-epicatechin
4. (+)-epicatechol
5. (2s,3s)-2-(3,4-dihydroxyphenyl)chroman-3,5,7-triol
6. Epicatechin, (+)-
7. (2s,3s)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2h-chromene-3,5,7-triol
8. Ld6b6tt8q5
9. Chembl129482
10. Chebi:76125
11. (2s,3s)-3,3',4',5,7-pentahydroxyflavan
12. Cis-2-(3,4-dihydroxyphenyl)chroman-3,5,7-triol
13. (2s,3s)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2h-1-benzopyran-3,5,7-triol
14. 2h-1-benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2s-cis)-
15. Catechin C
16. (-) Epicatechine
17. Dexepicatechin
18. (2s,3s)-epicatechin
19. Epicatechin, D-
20. Unii-ld6b6tt8q5
21. Dexepicatechin [inn]
22. Schembl862089
23. (2s,3s)-(+)-epicatechin
24. Ethyl Dichlorophosphorylcarbamate
25. Hy-n0001a
26. Dtxsid401316979
27. Zinc119978
28. Bdbm50135167
29. (+)-3 3' 4' 5 7-pentahydroxyflavan
30. (+)-cis-3,3',4',5,7-pentahydroxyflavan
31. Cs-0204063
32. N2101
33. C09728
34. (2s,3s)-3',4',5,7-tetrahydroxyflavan-3-ol
35. 99182e3e-bccb-48bb-89bf-7ddc933d48ff
36. Q27145771
37. (2s,3s)-2-(3,4-dihydroxyphenyl)chromane-3,5,7-triol
38. (2s,3s)-2-(3,4-dihydroxy-phenyl)-chroman-3,5,7-triol
39. (2s-cis)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2h-1-benzopyran-3,5,7-triol
| Molecular Weight | 290.27 g/mol |
|---|---|
| Molecular Formula | C15H14O6 |
| XLogP3 | 0.4 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 1 |
| Exact Mass | 290.07903816 g/mol |
| Monoisotopic Mass | 290.07903816 g/mol |
| Topological Polar Surface Area | 110 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 364 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Epirium has advanced its first clinical candidate EPM-01 (Epicatechin) in Becker muscular dystrophy and plans to follow with drug development targeting other disorders associated with mitochondrial dysfunction and tissue degeneration.
Lead Product(s): Epicatechin
Therapeutic Area: Genetic Disease Product Name: EPM-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Epirium
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 27, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Epirium
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Epirium has advanced its first clinical candidate EPM-01 (Epicatechin) in Becker muscular dystrophy and plans to follow with drug development targeting other disorders associated with mitochondrial dysfunction ...
Product Name : EPM-01
Product Type : Small molecule
Upfront Cash : Undisclosed
August 27, 2020
Details:
The Phase 1 open-label, dose-escalation study is evaluating the safety, preliminary clinical efficacy and potential biomarkers of three doses of EPM-01 in participants with Becker or Becker-like muscular dystrophy.
Lead Product(s): Epicatechin
Therapeutic Area: Musculoskeletal Product Name: EPM-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 1 open-label, dose-escalation study is evaluating the safety, preliminary clinical efficacy and potential biomarkers of three doses of EPM-01 in participants with Becker or Becker-like muscular dystro...
Product Name : EPM-01
Product Type : Small molecule
Upfront Cash : Not Applicable
August 12, 2020
Details:
The company's prior studies have shown that EB 002 can stimulate mitochondrial biogenesis, contributing to the restoration of tissue bioenergetics, thus upregulating key protein production.
Lead Product(s): Epicatechin
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The company's prior studies have shown that EB 002 can stimulate mitochondrial biogenesis, contributing to the restoration of tissue bioenergetics, thus upregulating key protein production.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
April 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
